Monday, February 06, 2012
 
Info for Pharma Companies Minimize

Continued pressure on NHS bed space and waiting lists creates an attractive opportunity for the drug industry to facilitate the treatment of patients at home. One way of achieving this is to consider investing a little more in your product development programmes, for example by utilising patient-friendly syringes or ready-to-use fixed rate infusions. In addition, review your existing portfolio to see if you have any candidates for home care. Home therapy often brings improved patient compliance, maximising therapeutic outcome and patient quality of life as well as minimising drug wastage.

Central Homecare has a proven track record of working with pharmaceutical companies in delivering both patient-centred home care services and specialist wholesaling. We are an established provider of high-tech services to patients requiring management of either simple or complex drug therapies in their own homes and provide an extensive range of ambulatory drug infusion systems, consumable equipment and comprehensive aseptic drug compounding services.


January 18th 2012 - Alliance Boots response to the Hacket report on 'Homecare Medicines' Minimize

Alliance Boots response to the Hacket report on “Homecare Medicines - Towards a Vision for the Future”.

You can download the full report here.


December 2nd 2011 - Department of Health’s Sponsored Review of NHS Homecare Medicines Minimize

Central Homecare welcomes the release of the Hacket report on “Homecare Medicines - Towards a Vision for the Future”.

You can download the full report here.


April 2011 - Central Homecare extends product offering for Rheumatoid Arthritis and Dermatology patients Minimize

Central Homecare has extended its product portfolio within its anti-TNF treatment range to now include Embrel®, Humira®, Cimzia® and Stelara®, for patients with rheumatoid arthritis and dermatological conditions.

Richard Huckle, Business Development Director, Central Homecare, commented:

“We are delighted to have extended our product offering within our anti-TNF range. We believe we are the fastest growing service provider, and believe we have the widest anti-TNF product portfolio, which enables us to provide customers with a real alternative within the market.”
 
“We put patients at the centre of everything we do - providing full training by our own dedicated nursing staff as well as offering full patient choice of delivery. We are very much looking forward to growing our product portfolio in this area, and continuing to support the treatment of patients in their own home.”

For further information please contact Central Homecare on 01420 543 400.


April 2011 - 10 ways Clinical Homecare can support your brands growth Minimize

Click the link to download '10 ways Clinical Homecare can support your brands growth - A practical guide by Gaurang Majmudar' - Download (200KB PDF)


Bringing you Closer Minimize

Central Homecare has the technology to bring you closer to patients, giving you the competitive advantage.

Central Homecare has already built long term relationships with a number of pharmaceutical companies, for example Pfizer, concerning the distribution of Genotropin® and Somavert® to patients at home and Ferring Pharmaceuticals for a selection of IVF treatments. Central Homecare also distributes Metoject® pre-filled syringes (methotrexate 50mg/ml) to patients at home in the UK on behalf of medac Gmbh.

Central Homecare is an ISO 9001:2008 accredited company so service quality is assured.


Copyright 2009 by Central Homecare Powered by Bison Grid Terms Of Use